In the largest retrospective evaluation of fatal ICIs-associated toxic effects published by the World Health Organization (WHO) pharmacovigilance database (Vigilyze), hepatitis accounted for around 20% of deaths of reported anti-PD-1/PD-L1 related fatalities (31). Here, PDCD1 is linked to hepatitis A virus infection.